SCHEMBL10149773

SCHEMBL10149773

O=C(Nc1cc(-c2n[nH]c(=O)c3ccccc23)ccc1N1CCCCCC1)C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 4/20 0.52
▸ ROCK2 O75116 2/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ MEN1 O00255 3/20 0.52
▸ HSD17B10 Q99714 2/20 0.52
▸ USP2 O75604 1/20 0.52
▸ ALDH1A1 P00352 4/20 0.52
▸ NPSR1 Q6W5P4 3/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ CYP2D6 P10635 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ HIF1A Q16665 1/20 0.52
▸ MAPT P10636 5/20 0.51
▸ TSHR P16473 2/20 0.51
▸ MAPK1 P28482 2/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ HTT P42858 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10149777 0.87 MAPT (0.66) ROCK1ROCK2KMT2AMEN1HSD17B10
SCHEMBL10149785 0.82 ROCK2 (0.46) ROCK1ROCK2KMT2AMEN1HSD17B10
SCHEMBL1660197 0.82 ALDH1A1 (0.47) ROCK1ROCK2KMT2AMEN1HSD17B10
SCHEMBL1658364 0.81 MEN1 (0.45) ROCK1ROCK2KMT2AMEN1HSD17B10
SCHEMBL1657083 0.80 ALDH1A1 (0.47) ROCK1ROCK2KMT2AMEN1HSD17B10
SCHEMBL10149784 0.79 CREBBP (0.52) ROCK1ROCK2KMT2AMEN1HSD17B10
SCHEMBL1657527 0.78 ALDH1A1 (0.59) ROCK1ROCK2KMT2AMEN1HSD17B10
SCHEMBL1657196 0.78 ALDH1A1 (0.54) ROCK1ROCK2KMT2AMEN1HSD17B10
SCHEMBL10149767 0.78 HTT (0.52) ROCK1ROCK2KMT2AHSD17B10ALDH1A1
SCHEMBL1658324 0.77 ROCK2 (0.56) ROCK1ROCK2KMT2AMEN1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140171419-A1 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLECULE MODULATORS HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY ANGION BIOMEDICA CORP (US) 2014-06-19 — — US disclosed
US-20120190668-A1 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLEUCLE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-07-26 — — US disclosed
US-8193177-B2 Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases ANGION BIOMEDICA CORP. (US) 2012-06-05 — — US disclosed
US-8193177-B2 Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases ANGION BIOMEDICA CORP. (US) 2012-06-05 — — US disclosed
WO-2011019400-A2 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLECULE MODULATORS HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY ANGION BIOMEDICA CORP. (US) 2011-02-17 — — WO disclosed
US-7879898-B1 treating a chronic obstructive pulmonary disease using modulators of HGF/SF activity; for example, 3-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one; emphysema ANGION BIOMEDICA CORP. (US) 2011-02-01 — — US disclosed
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES ANGION BIOMEDICA CORP. 2010-10-07 — — US disclosed
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES ANGION BIOMEDICA CORP. 2010-10-07 — — US disclosed
US-20100137285-A1 SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY ANGION BIOMEDICA CORP. (US) 2010-06-03 — — US disclosed
US-20100137285-A1 SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY ANGION BIOMEDICA CORP. (US) 2010-06-03 — — US disclosed
US-7648978-B2 Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone ANGION BIOMEDICA CORP. (US) 2010-01-19 — — US disclosed
US-7648978-B2 Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone ANGION BIOMEDICA CORP. (US) 2010-01-19 — — US disclosed
WO-2009064422-A2 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES ANGION BIOMEDICA CORP. (US) 2009-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190668-A1 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLEUCLE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY HGF, HDGF, HGFAC ROCK1 1207/4885ROCK2 1714/4885KMT2A 3997/4885
US-20100137285-A1 SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY HGF, IL2, IL2RA ROCK1 526/4885ROCK2 788/4885KMT2A 3896/4885
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES HGF, HDGF, HGFAC ROCK1 927/4885ROCK2 929/4885KMT2A 3623/4885
US-20140171419-A1 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLECULE MODULATORS HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY HGF, HDGF, MET ROCK1 1289/4885ROCK2 1298/4885KMT2A 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback